Loading clinical trials...

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception | Clinical Trials | Clareo Health

COMPLETED

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

NCT02375425•University of Pittsburgh

Summary

The development of surrogates to predict HIV prevention product safety and efficacy is a high priority. An ex vivo challenge model is one such promising surrogate. Colonic tissue exposed to rectally applied microbicides in vivo and then challenged with HIV in the lab showed significant reduction in HIV replication when compared to tissue exposed to placebo gel. Currently, the ex vivo challenge model for ectocervical and vaginal tissue is under development at the Dezzutti lab at the Magee Womens Research Institute in Pittsburgh, PA. Currently the Reproductive Infectious Disease Research Group is conducting a study designed to answer important questions about the ex vivo challenge model:which HIV virus is the best to use in the laboratory and what is the best indicator of HIV infection. The proposed study delineated here will investigate the effect of BV, HSV and contraceptive use on the model . There will be two arms to the study; the first will investigate the impact of HSV and BV status and the second, contraceptive use. Vaginal and cervical biopsies will be collected from participants for the ex vivo challenge model.

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. Age 18-45
•2. HIV uninfected. Note: if a woman participated in a recent research study and has an HIV test result available from that study, this will suffice provided the date of the test is within 6 months of the enrollment visit for this trial. Otherwise, the potential participant should undergo testing at the first study visit.
•3. Willing and able to give informed consent to take place in the study
•4. Willing to undergo a pelvic examination and genital biopsies and HIV and HSV testing
•5. Willing to provide contact information
•6. Agree to be sexually abstinent for two weeks beginning one week prior to the enrollment visit

Exclusion Criteria

•1. Menopausal
•2. Pregnant or within 90 days of last pregnancy
•3. Hysterectomy
•4. Use of a diaphragm, NuvaRing or spermicide for contraception
•5. Reports a course of antibiotic therapy in the 14 days prior to enrollment
•6. Known history of platelet disorder or bleeding disorder
•7. Participation in another microbicide or contraceptive study or a study involving cervical and/or vaginal biopsies within one month of enrollment
•8. Pelvic exam findings concerning for cervicitis including abnormal cervical discharge, erythema and edema
•9. Use of any spermicide or spermicide-lubricated condom within one week of enrollment.
•10. Use of any internal vaginal device or product with the exception of tampons within one week of enrollment
+1 more criteria

Locations (1)

Magee Womens Hospital of UPMC

Pittsburgh, Pennsylvania, United States

Key Dates

Start Date

June 1, 2015

Primary Completion Date

June 1, 2016

Completion Date

June 1, 2016

Last Updated

December 24, 2018

Enrollment

294

ACTUAL participants

Conditions

HIV

Interventions

no intervention

OTHER

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

RECRUITING

Thinking and Memory Problems in People With HIV

NCT01875588

HIV Positive

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

Inclusion Criteria

Exclusion Criteria

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Thinking and Memory Problems in People With HIV

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption